Martingale Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Martingale Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$807K	Buy	+44,935	New	+$850K	0.02%	574
2021 Q1	–	Sell	-3,801	Closed	-$649K	–	909
2020 Q4	$649K	Sell	3,801 -1,302	-26%	-$193K	0.01%	557
2020 Q3	$717K	Buy	5,103 +1,099	+27%	+$167K	0.01%	718
2020 Q2	$643K	Buy	+4,004	New	+$545K	0.01%	831
2019 Q2	–	Sell	-3,703	Closed	-$442K	–	1062
2019 Q1	$442K	Buy	+3,703	New	+$476K	﹤0.01%	900
2018 Q2	–	Sell	-10,607	Closed	-$786K	–	1013
2018 Q1	$786K	Buy	+10,607	New	+$707K	0.01%	762

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Martingale Asset Management's SRPT Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 44,935 shares worth $807K. The stake represents 0.02% of the portfolio and ranks #574 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in SRPT as recently as Q4 2020.

Martingale Asset Management first reported a position in SRPT in Q1 2018 and has held it in 6 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Martingale Asset Management held 44,935 shares of Sarepta Therapeutics worth $807K as of Q2 2026.
Sarepta Therapeutics was a new Martingale Asset Management position in Q2 2026.
Sarepta Therapeutics made up 0.02% of Martingale Asset Management's portfolio in Q2 2026, its #574 holding.
Martingale Asset Management first reported a position in Sarepta Therapeutics in Q1 2018 and has held it in 6 quarters since.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.